Stay updated on Nivolumab and Ipilimumab in ACC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Ipilimumab in ACC Clinical Trial page.

Latest updates to the Nivolumab and Ipilimumab in ACC Clinical Trial page
- ChecktodayChange DetectedA new Revision: v3.3.4 label was added and the previous Revision: v3.3.3 label was removed, indicating a minor site revision. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check7 days agoChange DetectedAn updated status block was added, displaying Northwestern University as sponsor and the last known status with a verification date (2023-12).SummaryDifference0.4%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedLocations section is reorganized under a general 'Locations' header and now lists Illinois as a study site, replacing the previous 'Illinois Locations' heading. The footer 'HHS Vulnerability Disclosure' link was removed and the revision label updated from v3.3.2 to v3.3.3.SummaryDifference0.2%

- Check50 days agoChange DetectedPublications section now clarifies that entries are automatically filled from PubMed and may not all pertain to the study. A revision tag 'Revision: v3.3.2' is displayed.SummaryDifference0.1%

- Check57 days agoChange DetectedRemoved a government funding–related notice stating information may not be up to date; study details on the page remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check72 days agoChange DetectedMinor formatting tweaks and updates to non-critical metadata were observed, and core study details such as title, NCT number, objectives, eligibility criteria, and primary outcomes remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Nivolumab and Ipilimumab in ACC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Ipilimumab in ACC Clinical Trial page.